CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 5 enrolled
Drug / intervention
PF-05089771 +1 moredrug
Likely dose
PF-05089771 1600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01769274
NCT01769274Phase 2Completed
CompareCT.gov

A RANDOMIZED, DOUBLE BLIND THIRD PARTY OPEN PLACEBO-CONTROLLED EXPLORATORY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SINGLE DOSES OF PF-05089771 IN PATIENTS WITH PRIMARY (INHERITED) ERYTHROMELALGIA

Pfizer·interventional·Posted Jan 16, 2013·Updated Nov 19, 2019

In Brief

A Phase 2 clinical trial evaluating PF-05089771 and Placebo for Inherited Erythromelalgia. Completed, enrolled 5 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of single doses of PF-05089771 against placebo in treatment of pain in patients with primary, inherited erythromelalgia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInherited Erythromelalgia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 16, 2013
Enrollment StartOct 22, 2012
Primary CompletionJul 12, 2013
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 13.5 years ago

Interventions

PF-05089771drug

A single oral dose of PF-05089771 1600 mg solution to be administered on Day 1 of each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of PF-05089771 will be adminstered.

Placebodrug

Placebo for PF-05089771 1600 mg solution administered in each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of placebo will be administered.